A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 162 With a Single Ascending Dose in Subjects With Chronic Hepatitis B Virus Infection
Sponsor: Yangshengtang Co., Ltd
Terminated
Enrollment difficulty
Listed as NCT06159062, this PHASE1 trial focuses on Chronic Hepatitis B Virus Infection and remains terminated or withdrawn. Sponsored by Yangshengtang Co., Ltd, it has been updated 6 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1
Status: Not Yet Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
Jan 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Yangshengtang Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .